Erythema migrans
Also known as: Erythema, Erythematous, Inflamed, Inflammation
Methodology & AI Transparency ⓘ
Erythema migrans Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Bacterial, Viral & Fungal Infections diagnostic criteria (A69.20), workup for Erythema migrans (also termed Erythema or Erythematous) integrates bacterial/fungal culture with in Erythema migrans (A69.20: antimicrobial susceptibility testing) with evidence-graded therapy tailored to Targeted PCR / in Erythema migrans (A69.20: Culture & Sensitivity) response.
- 2 Real-world patient consensus: Mapped to Bacterial, Viral & Fungal Infections under ICD-10-CM A69.20 for Erythema migrans clinical workups.
- 3 Typical cash cost range: Primary evaluation for Erythema migrans incorporates bacterial/fungal culture with in Erythema migrans (A69.20: antimicrobial susceptibility testing) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Erythema migrans: maintaining Targeted PCR / in Erythema migrans (A69.20: Culture & Sensitivity) within Pathogen clearance / negative test (A69.20).
Ask our AI Specialists anything about Erythema migrans
What Is Erythema migrans?
Under Bacterial, Viral & Fungal Infections diagnostic criteria (A69.20), workup for Erythema migrans (also termed Erythema or Erythematous) integrates bacterial/fungal culture with in Erythema migrans (A69.20: antimicrobial susceptibility testing) with evidence-graded therapy tailored to Targeted PCR / in Erythema migrans (A69.20: Culture & Sensitivity) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Erythema migrans (code A69.20) is cytokine pyrogen release [Erythema migrans A69.20], which Bacterial, Viral & Fungal Infections clinicians address while surveilling Targeted PCR / in Erythema migrans (A69.20: Culture & Sensitivity) (Pathogen clearance / negative test (A69.20)).
Common Symptoms & Clinical Signs
- • Presentation of Erythema migrans (A69.20): painful vesicular rash in Erythema migrans (A69.20: in a dermatomal)
- • Secondary Erythema migrans clinical sign: regional lymph node in Erythema migrans (A69.20: tenderness or acute)
- • Symptom flares in Erythema migrans correlating with Targeted PCR / in Erythema migrans (A69.20: Culture & Sensitivity) deviation outside Pathogen clearance / negative test (A69.20)
- • Functional infections & antivirals impact requiring bacterial/fungal culture with in Erythema migrans (A69.20: antimicrobial susceptibility testing) evaluation (A69.20)
Erythema migrans Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | A69.20 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NLM Clinical Tables |
| Diagnostic / Lab Marker: Targeted PCR / in Erythema migrans (A69.20: Culture & Sensitivity) | Pathogen clearance / negative test (A69.20) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Erythema migrans (A69.20: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (A69.20) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Erythema migrans (A69.20: Procalcitonin) | Resolution to baseline (A69.20) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Erythema migrans
Treatment selection for Erythema migrans depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Erythema migrans)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety profile of baricitinib in patients with systemic lupus erythematosus: an: What a 1,655-Participant Study Found The results of this integrated safety analysis in patients with SLE are not substantially different to the established safety profile of baricitinib. RMD open • 2023-08-15 • Phase III Randomized Trial | N = 1,655 | 96/100 | PMID 37604638 ↗ |
| New Insights on Anifrolumab reduces flare rates in patients with moderate to severe systemic: What a 366-Participant Study Found Analyses of pooled TULIP-1 and TULIP-2 data support that anifrolumab reduces flares while permitting glucocorticoid taper in patients with SLE. Lupus • 2021-07-15 • Phase III Randomized Trial | N = 366 | 93/100 | PMID 33977796 ↗ |
| New Insights on Benefits and safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus:: What a 367-Participant Study Found Consistent with the well-established profile of intravenous anifrolumab, subcutaneous anifrolumab demonstrated significant, clinically meaningful treatment benefits when added to standard therapy, and an acceptable safety... Arthritis & rheumatology (Hoboken, N.J.) • 2026-06-15 • Phase III Randomized Trial | N = 367 | 93/100 | PMID 41466456 ↗ |
| New Insights on Sub-setting systemic lupus erythematosus by combined molecular phenotypes defines: What a 1,747-Participant Study Found Combinatorial analysis of four molecular biomarkers revealed subsets of SLE patients that discriminated by disease manifestations, concomitant medication use, geography, time to severe flare and SRI-4 response. Rheumatology (Oxford, England) • 2021-11-03 • Phase III Randomized Trial | N = 1,747 | 90/100 | PMID 33580248 ↗ |
| Can This Approach Help? Inside the Latest Research on Disease activity and glucocorticoid tapering patterns in Japanese patients with In the Japanese subpopulation of the TULIP-2 trial, anifrolumab resulted in improvements in disease activity to those reported for the overall population, suggesting a beneficial effect for disease control. Modern rheumatology • 2025-04-08 • Phase III Randomized Trial | N = 24 | 88/100 | PMID 39801286 ↗ |
Erythema migrans Patient Community & “People Like Me” Threads
Filter Erythema migrans community threads and patient logs by age, biological sex, dosage, and treatment duration.